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Abstract
Infectious diseases are closely related to cancer. Human cytomegalovirus (HCMV) has been implicated in the promotion of tumour growth,
and is present in the tumour specimens of colorectal cancer (CRC). This study aimed to investigate whether tumoral presence of HCMV is
associated with a different clinical outcome in elderly patients with CRC. We analysed archived tumour specimens from 95 CRC patients
aged ≥65 years. HCMV was detected by PCR. Clinical, pathological, disease-free and overall survival data were compared between patients
with HCMV-positive and HCMV-negative tumours. A quantitative RT-PCR array was used to evaluate the expression levels of cytokines
genes of T-helper subpopulations in tumours. In the Kaplan–Meier analysis of the 81 patients who underwent curative surgery, 39 patients
with HCMV-positive tumours had a lower disease-free survival rate (p 0.024). For patients with stage II or stage III tumours, tumoral
HCMV status correlated with disease-free survival more closely than the traditional histopathological staging methods. In a multivariate
Cox proportional hazard model, tumoral presence of HCMV independently predicted tumour recurrence in 5 years (hazard ratio 4.42;
95% CI 1.54–12.69, p 0.006). The qRT-PCR analysis of ten stage II tumours showed that the gene expression levels of interleukin-17—the
signature cytokine of T-helper 17 cells—and its receptor, interleukin-17 receptor C, were higher in the ﬁve HCMV-positive tumours.
Our results suggest that the presence of HCMV in CRC is associated with poorer outcome in elderly patients. How the virus interacts with
the tumour microenvironment should be further investigated.
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Introduction
Infectious diseases are closely related to human cancers. The
WHO estimates that >15% of new cancer cases are attribut-
able to infectious diseases [1]. Infectious agents can participate
in the oncogenic process in diverse ways. Persistent infection
arouses inﬂammatory cascades that damage the genetic
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content of the host. Viruses such as human papillomaviruses
and hepatitis B virus directly invade cells, and stimulate cell
proliferation or inactivate tumour suppressor genes [2,3].
Microorganisms may also be involved in the oncogenic process
by modulating the host immune system, as in the case of
human immunodeﬁciency virus [4].
Human cytomegalovirus (HCMV), a herpesvirus that infects
60–90% of the general population, has been regarded as an
oncomodulatory virus because of its effects on cell-cycle
progression, mutagenesis, angiogenesis, and immune evasion
[5–7]. Genetic components or gene products of HCMV have
been detected in a number of human cancers [8–12]. Several
studies have identiﬁed HCMV in the tumour tissues of
colorectal cancer (CRC) [13–15]. We recently demonstrated
that >40% of CRC specimens were positive for HCMV. Viral
DNA was detected preferentially in tumoral specimens over
the adjacent non-neoplastic tissue [15]. Nevertheless, whether
tumoral infection with HCMV is associated with a different
clinical outcome is not clear. This study aimed to clarify
whether the tumoral presence of HCMV is associated with a
different clinical outcome. Here, we show that the tumoral
presence of HCMV is associated with shorter disease-free
survival after curative surgery in elderly CRC patients, and is
associated with higher levels of intratumoral interleukin
(IL)-17, the signature cytokine of the T-helper (TH)17 pathway,
which was recently found to be closely related to the
prognosis of CRC.
Materials and Methods
Study population and data collection
The study was approved by the Institutional Review Board of
Taipei Veterans General Hospital (VGHTPE). For HCMV
detection, tumour specimens from patients with CRC who
underwent primary resection between 2000 and 2010 were
randomly retrieved from the bank of residual surgical tissues at
the Division of Colorectal Surgery, VGHTPE. No restriction
was placed on gender, ethnicity, or disease staging. Demo-
graphic, clinical and pathological data were extracted from the
CRC database of the Division of Colorectal Surgery, VGHTPE.
These data had been recorded prospectively with regular
updates, and included patient demographic information,
underlying medical problems, details of surgery, characteristics
of the tumour, important pathological prognostic features, and
disease condition and survival at the last follow-up.
For tumour staging, the tumour-node-metastasis (TNM)
classiﬁcation was used [16]. Early metastasis was deﬁned by
the presence of vascular emboli, lymphatic invasion, and
perineural invasion, singly or in combination. The observation
time was the interval between the diagnosis and the last
follow-up or death. Data were censored at the last follow-up
for patients who had not shown relapse and for those who had
died. Disease-free survival was deﬁned as the period from the
date of surgery to the date of conﬁrmed tumour relapse for
patients with relapse, or from the date of surgery to the date
of the last follow-up for patients without detectable tumour.
Detection of HCMV in tumour specimens
Before undergoing primary resection, the patients had pro-
vided written informed consent. Intraoperatively, the tumour
mass was identiﬁed by the surgeon, and a small part
(approximately 500 mg) of the tumour tissue was resected
and stored at 70°C at the bank of residual surgical tissues at
the Division of Colorectal Surgery, VGHTPE. In this study, we
used 20–25 mg of tumour tissue obtained from these spec-
imens. Genomic DNA was extracted with a commercial kit
(QIAamp DNA mini kit; Qiagen, Germantown, MD, USA),
according to the manufacturer’s instructions. The resulting
DNA extracts were stored at 80°C until use.
To detect HCMV, PCR was carried out with primers
targeting the viral genes UL55, UL73, and UL144, as previously
described [15]. The reaction was carried out over 35 cycles
(95°C for 1.5 min, 55°C for 2 min, and 72°C for 1 min, with
an initial temperature of 95°C for 5 min, and an additional
10 min at 72°C in the last cycle) in a thermal cycler (GeneAmp
PCR system 9600; Life Technologies, Carlsbad, CA, USA). The
products were then gel-electrophoresed, stained, and photo-
graphed. The presence of HCMV was deﬁned as positive PCR
results for any of three viral genes tested.
Analysis of TH cytokines and pathways
After homogenization of the tumour specimens, total RNA
was extracted with a QIAamp mini kit (Qiagen), and
reverse-transcribed with an ABI High Capacity cDNA reverse
transcription kit (Life Technologies). The resulting cDNA was
analysed with a 96-well plate quantitative PCR array (Human
TH17 Response RT
2 Proﬁler PCR array; Qiagen), according to
the manufacturer’s instructions. The array includes 84 key
genes of cytokines and signal pathways of major CD4+ T-cell
subsets (Table S1). Expression levels of genes were quantiﬁed
on the basis of intercalation of SYBR Green on an ABI 7000
real-time PCR system (Life Technologies), and analysed with
the vendor’s web-based software module. The relative level of
mRNA expression for each gene was normalized to the
expression level of the reference gene b-actin.
Statistical analysis
Categorical variables were compared by use of the chi-squared
test with Fisher’s exact test. Continuous variables were
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compared by use of the t-test for data that followed the
normal distribution, and the Mann–Whitney U-test for data
that did not follow the normal distribution. Survival was
evaluated with the Kaplan–Meier method, and signiﬁcant
differences in survival curves were evaluated with the
Mantel–Cox log rank test. A Cox proportional hazard
regression model with forward stepwise selection procedures
was used to identify risk factors for 5-year mortality. A p-value
of <0.1 in the univariate analysis was required for a variable to
be entered into the multivariate model. To reduce the right
skewness in the multivariate analysis, patient age and preop-
erative carcinoembryonic antigen (CEA) levels were trans-
formed into quartiles. A p-value of <0.05 indicated a signiﬁcant
difference. All analyses were carried out with SPSS 18.0 for
Windows (IBM-SPSS, Chicago, IL, USA).
Results
The percentage of HCMV-positive tumours was increased in
elderly patients
For the 95 patients aged ≥65 years, HCMV was detected in
45.3% (43/95) of the tumour samples. We divided the patients
according to age quartiles. The mean ages were
73.6  4.3 years for the ﬁrst three quartiles (n = 72), and
83.9  3.8 years for the fourth quartile (n = 23). The per-
centage of HCMV-positive tumours in patients of the eldest
quartile was signiﬁcantly higher than that in patients of of the
ﬁrst three quartiles (15/23 vs. 28/72, p 0.013; Fig. 1a).
Clinical and pathological features of CRC with and without
HCMV infection
The demographic characteristics and underlying diseases of the
patients are shown in Table 1. The preoperative levels of CEA
were not different between patients with HCMV-positive and
HCMV-negative tumours (p 0.71). Pathological examination
revealed that all of the tumours were adenocarcinomas. The
tumoral presence of HCMV was not associated with a different
grade of differentiation (p 0.33), the intratumoral inﬂammatory
response (p 0.43), or pathological signs of early metastasis.
Furthermore, the HCMV-positive and HCMV-negative
tumours did not differ with respect to the local extent of
the tumour (T) or regional lymph node metastasis (N). A
lower frequency of distant metastasis (stage IV disease,
p 0.032) and a higher frequency of stage III disease were
observed in the patients with HCMV-positive tumours
(Fig. 1b). In the 81 patients who underwent curative surgery,
the demographic characteristics, frequency of underlying
disease and clinical and pathological features did not differ
according to the tumoral presence of HCMV.
Tumoral presence of HCMV was associated with shorter
disease-free survival in elderly patients treated with curative
surgery
The median follow-up duration was 32.9 months (range,
0.5119.9 months) for patients with HCMV-positive tumours,
and 31.0 months (range, 1.9119.3 months) for those with
HCMV-negative tumours. In the Kaplan–Meier analysis of the
81 patients who underwent curative surgery, those with
HCMV-positive tumours had a lower disease-free (or
tumour-free) survival rate (p 0.024; Fig. 2a). This difference
was even more signiﬁcant in the 71 patients who had no
distant metastasis at the time of surgery (p 0.0075; Fig.2b).
To further characterize the association between HCMV and
the outcome of CRC, the patients were stratiﬁed according to
the TNM classiﬁcation. The Kaplan–Meier curves showed
different disease-free survival rates in the four major CRC
(a)
(b)
FIG. 1. Distribution of human cytomegalovirus (HCMV)-positive and
HCMV-negative tumours according to (a) age quartiles and (b) tumour
stages. The average patient ages in the three younger quartiles and
oldest quartile were 73.6  4.3 years and 83.9  3.8 years, respec-
tively. For distribution according to tumour stage, the data of the
elderly patients with colorectal cancer who underwent curative
surgery were analysed.
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stages (Fig. 3a). Regardless of the tumoral presence of HCMV,
stage IV tumours were associated with a poor outcome,
whereas stage I tumours showed a favourable outcome
(Fig. 3b). On the other hand, for patients with stage II or III
tumours, the tumoral presence of HCMV was associated with
a poorer outcome (Fig. 3c). Further stratiﬁcation in each stage
revealed that the disease-free survival was closely associated
with the tumoral presence of HCMV but not with the local
extent of the tumour or regional lymph node metastasis in
these patients (Fig.3d).
Tumoral presence of HCMV independently predicted tumour
recurrence in elderly patients treated with curative surgery
Univariate and multivariate Cox proportional hazard models
were used to assess the risk of 5-year cancer recurrence in
patients who underwent curative surgery. Age and the
preoperative CEA level were transformed into quartiles.
Among the risk factors analysed, the tumoral presence of
HCMV was independently associated with 5-year disease
recurrence in these patients (Table 2, Fig. 4); the hazard ratio
(HR) for disease recurrence was 4.42 (95% CI 1.54–12.69;
p 0.006). Other factors that were independently associated
with 5-year disease recurrence were preoperative CEA
level (HR 2.06; 95% CI 1.26–3.37; p 0.008) and distant
metastasis at the time of surgery (HR 5.50; 95% CI 1.55–
19.51; p 0.004).
The TH17 pathway was activated in HCMV-positive tumours
Na€ıve CD4+ T-cells differentiate into several subsets, including
TH1 cells, TH2 cells, regulatory T-cells, and a recently
TABLE 1. Age-speciﬁc demographic characteristics and underlying diseases of colorectal cancer (CRC) patients aged ≥65 years
Characteristics
Overall patients
p
Patients who underwent curative
surgery
p
HCMV detected
in tumour
n = 43
HCMV not detected
in tumour
n = 52
HCMV detected
in tumour
n = 39
HCMV not detected
in tumour
n = 42
Male sex, no. (%) 33 (76.7) 36 (69.2) 0.49 31 (76.5) 28 (66.7) 0.22
Age (years), mean  SD 76.7  7.0 75.6  5.3 0.40 77.1  6.9 75.8  5.1 0.32
Diabetes mellitus, no. (%) 7 (16.3) 11 (21.2) 0.54 7 (17.9) 9 (21.4) 0.78
Hypertension, no. (%) 21 (48.8) 20 (38.5) 0.41 21 (53.8) 18 (42.9) 0.38
Heart disease, no. (%) 7 (16.3) 11 (21.2) 0.61 7 (17.9) 11 (26.2) 0.43
Lung disease, no. (%) 3 (7.0) 3 (5.8) 1.00 3 (7.7) 3 (7.1) 1.00
Renal disease, no. (%) 2 (4.7) 3 (5.8) 1.00 2 (5.1) 2 (4.8) 1.00
Liver disease, no. (%) 1 (2.3) 0 (0.0) 0.45 1 (2.6) 0 (0.0) 0.48
Central nervous system disease, no. (%) 5 (11.6) 3 (5.8) 0.46 5 (12.8) 3 (7.1) 0.47
History of polyp or CRC, no. (%) 1 (2.3) 0 (0.0) 1.00 1 (2.6) 0 (0.0) 0.48
History of other malignancy, no. (%) 3 (7.0) 7 (13.5) 0.50 2 (5.1) 7 (16.7) 0.16
Curative surgery, no. (%) 39 (90.7) 42 (80.8) 0.25 NA NA NA
Ascending colon cancer, no. (%) 15 (34.9) 14 (26.9) 0.50 14 (35.9) 9 (21.4) 0.22
Rectal cancer, no. (%) 11 (25.6) 16 (30.8) 0.65 10 (25.6) 12 (28.6) 0.81
Poorly differentiated tumour, no. (%) 3 (7.0) 1 (1.9) 0.33 3 (7.7) 1 (1.9) 0.33
Signiﬁcant inﬂammation in tumour, no. (%) 10 (23.3) 8 (15.4) 0.43 9 (23.1) 8 (19.0) 0.79
Pathological signs of early metastasis: VELIPIa, no. (%) 7 (9.5) 14 (11.5) 0.32 5 (12.8) 9 (21.4) 0.38
Advanced local invasion (T4), no. (%) 2 (4.7) 10 (19.2) 0.06 2 (5.1) 6 (14.3) 0.27
Lymph node metastasis, no. (%) 20 (46.5) 23 (44.2) 0.84 18 (46.2) 14 (33.3) 0.26
Distant metastasis (stage IV), no. (%) 6 (14.0) 18 (34.6) 0.032 2 (5.1) 8 (19.0) 0.059
HCMV, human cytomegalovirus; NA, not applicable; SD, standard deviation.
aVELIPI represents pathological features of early metastatic invasion, including vascular emboli, lymphatic invasion, and perineural invasion, alone or in combination.
(a) (b)
FIG. 2. Kaplan–Meier curves of disease-free survival. (a) Patients with colorectal cancer who underwent curative surgery (n = 81). (b) Patients
without distant metastasis (stage I–III tumours) at the time of surgery (n = 71). HCMV, human cytomegalovirus.
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characterized subset, TH17 cells [17]. The expression levels of
the signature cytokines and key transcription factors of TH
subpopulations were compared between ﬁve HCMV-positive
and ﬁve HCMV-negative tumours, by use of a quantitative PCR
array. Of the 84 genes tested, most (74/84, 88.1%) were
upregulated in HCMV-positive tumours. The expression levels
showed signiﬁcant differences in ﬁve genes: those encoding
IL-17A, IL-17 receptor C, signal transducer and activator of
transcription (STAT)3, STAT5A, and STAT6. Speciﬁcally, the
levels of the signature cytokine of TH17 cells, IL-17A, and one
of its receptors, IL-17 receptor C, were higher in HCMV-po-
sitive tumours, whereas those of the TH1 cells, TH2 cells and
regulatory T-cells were not (Fig. 5).
Discussion
In the present study, for the ﬁrst time, we have demonstrated
that the tumoral presence of HCMV is associated with a poor
clinical outcome in elderly patients with CRC. The difference
in disease-free survival was mainly observed in patients with
stage II and III tumours. By the Cox proportional hazard
model, the tumoral presence of HCMV is among the few
(a) (c)
(b) (d)
FIG. 3. Kaplan–Meier curves of disease-free survival. (a) All patients stratiﬁed according to tumour stage. (b) Patients with stage I and IV tumours
stratiﬁed according to the tumoral presence of human cytomegalovirus (HCMV). (c, d) Patients with stage II and III tumours stratiﬁed according to
the tumoral presence of HCMV. ns, not signiﬁcant.
TABLE 2. Cox proportional hazard models for prediction of
5-year disease recurrence in elderly CRC patients receiving
curative surgery
Variable
Univariate
Cox model
Multivariate
Cox model
HR (95% CI) p HR (95% CI) p
HCMV in tumour
(yes/no)
2.54 (1.10–5.91) 0.030 4.42 (1.54–12.69) 0.006
TNM stage (IIV) 2.15 (1.32–3.51) 0.002 1.31 (0.34–5.11) 0.698
Lymph node
involvement (yes/no)
2.09 (1.32–3.30) 0.002 1.61 (0.30–8.61) 0.578
Distant metastasis
(yes/no)
4.78 (1.80–12.67) 0.002 5.50 (1.55–19.51) 0.004
Tumour gradea 3.90 (1.16–13.10) 0.028 2.81 (0.60–13.13) 0.191
Vascular emboli
(yes/no)
4.85 (1.75–13.46) 0.002 1.06 (0.22–5.01) 0.942
Preoperative CEA,
quartile
2.40 (1.50–3.85) <0.001 2.06 (1.26–3.37) 0.008
CEA, carcinoembryonic antigen; HCMV, human cytomegalovirus; HR, hazard ratio.
aWell, moderately or poorly differentiated.
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FIG. 4. Results of the multivariate hazard ratio analysis of 5-year disease recurrence. Factors inﬂuencing the outcome of colorectal cancer were
analysed. CEA, carcinoembryonic antigen; HCMV, human cytomegalovirus.
FIG. 5. Relative gene expression levels of major cytokines and signal transducers of T-cell subsets in human cytomegalovirus (HCMV)-positive
tumours (n = 5) and HCMV-negative tumours (n = 5). The relative expression level of each gene was normalized by the median level in the
HCMV-negative tumours. IFN, interferon; IL, interleukin; IL17RC, IL-17 receptor C; STAT, signal transducer and activator of transcription; TNF,
tumour necrosis factor.
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factors that independently predict 5-year disease recurrence
after curative surgery.
A profound interaction occurs between HCMV and the
host, especially in the elderly. Age is among the important
factors in the control of herpesvirus infection. HCMV reac-
tivates more frequently as the effectiveness of cell-mediated
immunity declines with age [18,19]. This may explain why very
elderly patients more frequently acquire HCMV-positive
tumours.
The next question concerns the possible inﬂuence of the
virus when it resides in the tumour tissue. In this study, we
found that the expression levels of IL-17A, the signature
cytokine of TH17 cells, were higher in HCMV-positive
tumours. TH17 cells play a critical role in mucosal immunity,
and their activation correlates with a poor outcome of CRC
[20–22]. Both animal and clinical studies have shown that
cytomegalovirus infection activates the production of IL-17
[23,24]. Whether HCMV is among the factors that modulate
T-cell immunity in the tumour microenvironment of CRC
should be further studied.
This study has some limitations. First, although the tumoral
presence of HCMV was associated with a poor clinical
outcome and a perturbed TH17 pathway, its causative role
could not be ascertained. Infection or reactivation of HCMV
may occur secondarily to the disturbed signal pathways and
suppressed immunity in the tumour microenvironment. In
addition, age is an important factor that affects both cancer
outcome and the status of HCMV infection. It is also possible
that the age-related immune decline, rather than HCMV-re-
lated oncomodulation, leads to the poor outcome of patients.
Second, because we focused only on elderly patients, the
ﬁndings cannot be extrapolated to all populations of patients
with CRC. The association between HCMV and the outcome
of CRC in young patients remains unclear.
Nevertheless, the results of this study provide novel insights
into the pathophysiology of CRC, and indicate new directions
for future studies. It is well known that HCMV infection
induces signiﬁcant phenotypic and functional alterations in
T-cell immunity, especially in the elderly [25]. Interestingly,
such HCMV-induced immune changes were similar to those
observed in cancer patients [26–28]. In CRC, changes in the
tumour microenvironment play a critical role in both cancer
behaviour and clinical outcome. The adaptive immune
response in the tumour inﬂuences outcome, regardless of
the tumour stage [29]. However, the underlying forces driving
the changes in the tumour microenvironment remain obscure.
Whether viral infection participates in the cross-talk between
cancer cells and the tumour microenvironment should be
further investigated, especially as accumulating evidence indi-
cates that HCMV may be a promotor of human cancer [30].
In conclusion, the tumoral presence of HCMV is associated
with an unfavourable outcome in elderly patients with CRC.
The virus may perturb the intratumoral TH17 pathway.
Further in vitro and in vivo studies are warranted to clarify
how the virus interacts with the host in the tumour
microenvironment of CRC.
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